PB006:一种纳塔利祖马布生物类似剂
1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. demail@springer.com.
Clinical drug investigation
|April 29, 2024
概括
泰鲁科 (PB006) 是第一种与纳塔利祖马布生物相似药物,在治疗复发性复发性多发性硬化症 (RRMS) 中具有类似的安全性和有效性. 这种生物仿制药为RRMS患者提供了可比的治疗选择.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 神经学 神经学
背景情况:
- 纳塔拉利祖马布是高度活跃的复发性复发性多发性硬化症 (RRMS) 的一项成熟疗法.
- 生物类似药的发展为增加治疗选择和可获得性提供了潜在的机会.
研究的目的:
- 评估PB006 (Tyruko®) 的疗效,安全性,耐受性和免疫性,PB006 (Tyruko®) 是纳塔利祖马布的生物类似物.
- 确认PB006作为RRMS成年人的可比治疗选择.
主要方法:
- 物理化学,药理动力学和药理动力学性质的比较评估.
- 在RRMS患者中进行临床研究以评估疗效和安全性.
- 从纳塔利祖马布转换为PB006.6. 的评估.
主要成果:
- PB006表现出与纳塔利祖马布相似的物理化学和药理动力学特征.
- 在健康人群中证实了药物动力学相似性.
- 在RRMS患者中,临床疗效和安全性概况与natalizumab相似.
- 切换到PB006并没有对耐受性或免疫性产生负面影响.
结论:
- PB006是一种安全有效的生物类似替代品,用于管理高度活跃的RRMS.
- 纳塔利祖马布在RRMS中既定的作用是由这种生物类似药的可用性补充的.
更多相关视频
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
1.2K
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
5.0K
相关概念视频
Bioequivalence: Overview
1.0K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.0K
Antiepileptic Drugs: Potassium Channel Activators
176
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
176
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
449
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
449
